Management of severe sepsis of abdominal origin

Scandinavian Journal of Surgery

Volumn 96, Issue 3, 2007, Pages 184-196

  Pieracci, F M ^a   Barie, Philip S ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Activated protein; Antibiotics; Critical care; Intra abdominal infection; Laparotomy; Peritonitis; Sepsis; Source control

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFOTETAN; CEFOXITIN; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; ERTAPENEM; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; PROTEIN C; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TIMENTIN;

ABDOMINAL INFECTION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST; HUMAN; LAPAROTOMY; MORTALITY; PERITONITIS; REVIEW; SEPSIS;

EID: 35148870871     PISSN: 14574969     EISSN: None     Source Type: Journal    
DOI: 10.1177/145749690709600302     Document Type: Review

References (113)

1. Barie PS, Hydo LJ, Shou J, Eachempati SR: Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis. Surg Infect 2006;7 Suppl 2:S77-80
2. Barie PS, Vogel SB, Dellinger EP, et al: A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group. Arch Surg 1997;132:1294-1302
3. Farthmann EH, Schoffel U: Principles and limitations of operative management of intraabdominal infections. World J Surg 1990;14:210-217
4. Garcia-Sabrido JL, Tallado JM, Christou NV, et al: Treatment of severe intra-abdominal sepsis and/or necrotic foci by an 'open-abdomen' approach. Zipper and zipper-mesh techniques. Arch Surg 1988;123:152-156
5. Marshall JC, Maier RV, Jimenez M, Dellinger EP: Source control in the management of severe sepsis and septic shock: an evidence-based review. Crit Care Med 2004;32:S513-526
6. Calandra T, Cohen J: The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med 2005;33:1538-1548
7. Solomkin JS, Hemsell DL, Sweet R, et al: Evaluation of new anti-infective drugs for the treatment of intraabdominal infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992;15 Suppl 1:S33-42
8. Merlino JI, Yowler CJ, Malangoni MA: Nosocomial infections adversely affect the outcomes of patients with serious intraabdominal infections. Surg Infect 2004;5:21-27
9. Nathens AB, Rotstein OD, Marshall JC: Tertiary peritonitis: clinical features of a complex nosocomial infection. World J Surg 1998;22:158-163
10. van Ruler O, Lamme B, Gouma DJ, et al: Variables associated with positive findings at relaparotomy in patients with secondary peritonitis. Critical Care Medicine 2007;35:468-476
11. Pacelli F, Doglietto GB, Alfieri S, et al: Prognosis in intraabdominal infections. Multivariate analysis on 604 patients. Arch Surg 1996;131:641-645
12. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874
13. Wacha H, Hau T, Dittmer R, Ohmann C: Risk factors associated with intraabdominal infections: a prospective multicenter study. Peritonitis Study Group. Langenbecks Arch Surg 1999;384:24-32
14. Schoeffel U, Jacobs E, Ruf G, et al: Intraperitoneal micro-organisms and the severity of peritonitis. Eur J Surg 1995;161:501-508
15. Adkins AL, Robbins J, Villalba M, et al: Open abdomen management of intra-abdominal sepsis. Am Surg 2004;70:137-140; discussion 140
16. Bohnen J, Boulanger M, Meakins JL, McLean AP: Prognosis in generalized peritonitis. Relation to cause and risk factors. Arch Surg 1983;118:285-290
17. Christou NV, Barie PS, Dellinger EP, et al: Surgical Infection Society intra-abdominal infection study. Prospective evaluation of management techniques and outcome. Arch Surg 1993;128:193-198; discussion 198-199
18. Mulier S, Penninckx F, Verwaest C, et al: Factors affecting mortality in generalized postoperative peritonitis: multivariate analysis in 96 patients. World J Surg 2003;27:379-384
19. Sotto A, Lefrant JY, Fabbro-Peray P, et al: Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis. J Antimicrob Chemother 2002;50:569-576
20. Mosdell DM, Morris DM, Voltura A, et al: Antibiotic treatment for surgical peritonitis. Ann Surg 1991;214:543-549
21. Montravers P, Chalfine A, Gauzit R, et al: Clinical and therapeutic features of nonpostoperative nosocomial intra-abdominal infections. Ann Surg 2004;239:409-416
22. Thompson SK, Chang EY, Jobe BA: Clinical review: Healing in gastrointestinal anastomoses, part I. Microsurgery 2006;26:131-136
23. Vignali A, Fazio VW, Lavery IC, et al: Factors associated with the occurrence of leaks in stapled rectal anastomoses: a review of 1,014 patients. J Am Coll Surg 1997;185:105-113
24. Alves A, Panis Y, Trancart D, et al: Factors associated with clinically significant anastomotic leakage after large bowel resection: multivariate analysis of 707 patients. World J Surg 2002;26:499-502
25. Roehrborn A, Thomas L, Potreck O, et al: The microbiology of postoperative peritonitis. Clin Infect Dis 2001;33:1513-1519
26. Wittmann DH, Aprahamian C, Bergstein JM: Etappenlavage: advanced diffuse peritonitis managed by planned multiple laparotomies utilizing zippers, slide fastener, and Velcro analogue for temporary abdominal closure. World J Surg 1990;14:218-226
27. Ohmann C, Wittmann DH, Wacha H: Prospective evaluation of prognostic scoring systems in peritonitis. Peritonitis Study Group. Eur J Surg 1993;159:267-274
28. Gajic O, Urrutia LE, Seward H, et al: Acute abdomen in the medical intensive care unit. Crit Care Med 2002;30:1187-1190
29. Montravers P, Gauzit R, Muller C, et al: Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996;23:486-494
30. Plotkin L: Epidemiology of abdominal sepsis. Vestn Khir Im I I Grek 2006;165:23-26
31. Anaya DA, Nathens AB: Risk factors for severe sepsis in secondary peritonitis. Surg Infect 2003;4:355-362
32. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-1310
33. Slade E, Tamber PS, Vincent JL: The Surviving Sepsis Campaign: raising awareness to reduce mortality. Crit Care 2003;7:1-2
34. Plotkin L: Course and outcome of surgical infections complicated with sepsis. Khirurgiia (Mosk) 2006:67-70
35. Edbrooke DL, Hibbert CL, Kingsley JM, et al: The patient-related costs of care for sepsis patients in a United Kingdom adult general intensive care unit. Crit Care Med 1999;27:1760-1767
36. Rau B, Pralle U, Mayer JM, Beger HG: Role of ultrasonographically guided fine-needle aspiration cytology in the diagnosis of infected pancreatic necrosis. Br J Surg 1998;85:179-184
37. Berger D, Buttenschoen K: Management of abdominal sepsis. Langenbecks Arch Surg 1998;383:35-43
38. Brooks G, Butel J, Morse S: Jawetz, Melnick & Adelberg's Medical Microbiology. Stamford: Appleton & Lange, 1998
39. Rossi F, Baquero F, Hsueh PR, et al: In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 2006;58:205-210
40. Tellado JM: The need for new antimicrobials for intra-abdominal infections (IAI): defining the forthcoming scenario. Surg Infect 2006;7:1-4
41. Dela Pena AS, Asperger W, Kockerling F, et al: Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention. J Gastrointest Surg 2006;10:567-574
42. Thadepalli H, Gorbach SL, Broido PW, et al: Abdominal trauma, anaerobes, and antibiotics. Surg Gynecol Obstet 1973;137:270-276
43. Berne TV, Yellin AE, Appleman MD, et al: Surgically treated gangrenous or perforated appendicitis. A comparison of aztreonam and clindamycin versus gentamicin and clindamycin. Ann Surg 1987;205:133-137
44. Sitges-Serra A, Lopez MJ, Girvent M, et al: Postoperative enterococcal infection after treatment of complicated intraabdominal sepsis. Br J Surg 2002;89:361-367
45. Peoples JB: Candida and perforated peptic ulcers. Surgery 1986;100:758-764
46. Dupont H, Bourichon A, Paugam-Burtz C, et al: Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med 2003;31:752-757
47. Montravers P, Dupont H, Gauzit R, et al: Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006;34:646-652
48. Dupont H, Paugam-Burtz C, Muller-Serieys C, et al: Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients. Arch Surg 2002;137:1341-1346; discussion 1347
49. Fry DE, Pearlstein L, Fulton RL, Polk HC, Jr: Multiple system organ failure. The role of uncontrolled infection. Arch Surg 1980;115:136-140
50. Barkhausen J, Stoblen F, Dominguez-Fernandez E, et al: Impact of CT in patients with sepsis of unknown origin. Acta Radiol 1999;40:552-555
51. Lal NR, Kazerooni EA, Bree RL: Development and implementation of an appropriateness guideline for use of CT in cases of suspected intraabdominal abscess. Acad Radiol 2000;7:711-716
52. Dougherty SH: Antimicrobial culture and susceptibility testing has little value for routine management of secondary bacterial peritonitis. Clin Infect Dis 1997;25 Suppl 2:S258-261
53. Falagas ME, Barefoot L, Griffith J, et al: Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis 1996;15:913-921
54. Pitcher WD, Musher DM: Critical importance of early diagnosis and treatment of intra-abdominal infection. Arch Surg 1982;117:328-333
55. Barie PS, Williams MD, McCollam JS, et al: Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg 2004;188:212-220
56. Stone HH, Mullins RJ, Dunlop WE, Strom PR: Extraperitoneal versus transperitoneal drainage of the intra-abdominal abscess. Surg Gynecol Obstet 1984;159:549-552
57. Olak J, Christou NV, Stein LA, et al: Operative vs percutaneous drainage of intra-abdominal abscesses. Comparison of morbidity and mortality. Arch Surg 1986;121:141-146
58. Hemming A, Davis NL, Robins RE: Surgical versus percutaneous drainage of intra-abdominal abscesses. Am J Surg 1991;161:593-595
59. Bufalari A, Giustozzi G, Moggi L: Postoperative intraabdominal abscesses: percutaneous versus surgical treatment. Acta Chir Belg 1996;96:197-200
60. Kok KY, Yapp SK: Laparoscopic drainage of postoperative complicated intra-abdominal abscesses. Surg Laparosc Endosc Percutan Tech 2000;10:311-313
61. Koperna T, Schulz F: Relaparotomy in peritonitis: prognosis and treatment of patients with persisting intraabdominal infection. World J Surg 2000;24:32-37
62. Hinck D, Struve R, Gatzka F, Schurmann G: Vacuum-assisted fascial closure in the management of diffuse peritonitis. Zentralbl Chir 2006;131 Suppl 1:S108-110
63. Mughal MM, Bancewicz J, Irving MH: 'Laparostomy': a technique for the management of intractable intra-abdominal sepsis. Br J Surg 1986;73:253-259
64. Cheatham ML, Safcsak K, Brzezinski SJ, Lube MW: Nitrogen balance, protein loss, and the open abdomen. Crit Care Med 2007;35:127-131
65. van Goor H, Hulsebos RG, Bleichrodt RP: Complications of planned relaparotomy in patients with severe general peritonitis. Eur J Surg 1997;163:61-66
66. Sautner T, Gotzinger P, Redl-Wenzl EM, et al: Does reoperation for abdominal sepsis enhance the inflammatory host response? Arch Surg 1997;132:250-255
67. Schein M: Planned reoperations and open management in critical intra-abdominal infections: prospective experience in 52 cases. World J Surg 1991;15:537-545
68. Rakic M, Popovic D, Rakic M, et al: Comparison of on-demand vs planned relaparotomy for treatment of severe intraabdominal infections. Croat Med J 2005;46:957-963
69. Hau T, Ohmann C, Wolmershauser A, et al: Planned relaparotomy vs relaparotomy on demand in the treatment of intraabdominal infections. The Peritonitis Study Group of the Surgical Infection Society-Europe. Arch Surg 1995;130:1193-1196; discussion 1196-1197
70. Lamme B, Boermeester MA, Belt EJ, et al: Mortality and morbidity of planned relaparotomy versus relaparotomy on demand for secondary peritonitis. Br J Surg 2004;91:1046-1054
71. Lamme B, Boermeester MA, Reitsma JB, et al: Meta-analysis of relaparotomy for secondary peritonitis. Br J Surg 2002;89:1516-1524
72. Bunt TJ: Urgent relaparotomy: the high-risk, no-choice operation. Surgery 1985;98:555-560
73. Bunt TJ: Non-directed relaparotomy for intra-abdominal sepsis. A futile procedure. Am Surg 1986;52:294-298
74. Hinsdale JG, Jaffe BM: Re-operation for intra-abdominal sepsis. Indications and results in modern critical care setting. Ann Surg 1984;199:31-36
75. Besselink MG, van Santvoort HC, Witteman BJ, Gooszen HG: Management of severe acute pancreatitis: it's all about timing. Curr Opin Crit Care 2007;13:200-206
76. Mier J, Leon EL, Castillo A, et al: Early versus late necrosectomy in severe necrotizing pancreatitis. Am J Surg 1997;173:71-75
77. Jimenez MF, Marshall JC: Source control in the management of sepsis. Intensive Care Med 2001;27 Suppl 1:S49-62
78. Biondo S, Jaurrieta E, Marti Rague J, et al: Role of resection and primary anastomosis of the left colon in the presence of peritonitis. Br J Surg 2000;87:1580-1584
79. Schilling MK, Maurer CA, Kollmar O, Buchler MW: Primary vs. secondary anastomosis after sigmoid colon resection for perforated diverticulitis (Hinchey Stage III and IV): a prospective outcome and cost analysis. Dis Colon Rectum 2001;44:699-703; discussion 703-695
80. Gooszen AW, Tollenaar RA, Geelkerken RH, et al: Prospective study of primary anastomosis following sigmoid resection for suspected acute complicated diverticular disease. Br J Surg 2001;88:693-697
81. Yellin AE, Hassett JM, Fernandez A, et al: Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults. Int J Antimicrob Agents 2002;20:165-173
82. Solomkin JS, Yellin AE, Rotstein OD, et al: Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 2003;237:235-245
83. DiNubile MJ, Chow JW, Satishchandran V, et al: Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections. Antimicrob Agents Chemother 2005;49:3217-3221
84. Solomkin JS, Mazuski JE, Baron EJ, et al: Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003;37:997-1005
85. Mazuski JE, Sawyer RG, Nathens AB, et al: The Surgical Infection Society guidelines on antimicrobial therapy for intraabdominal infections: evidence for the recommendations. Surg Infect 2002;3:175-233
86. Barie PS: Serious intra-abdominal infections. Curr Opin Crit Care 2001;7:263-267
87. Barie PS: Management of complicated intra-abdominal infections. J Chemother 1999;11:464-477
88. Bailey JA, Virgo KS, DiPiro JT, et al: Aminoglycosides for intra-abdominal infection: equal to the challenge? Surgical infections 2002;3:315-335
89. Paul M, Benuri-Silibiger I, Soares-Weiser K, Leibovici L: Beta-lactam monotherapy versus beta-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: Systematic review and meta-analysis of randomized trials. BMJ 2004;328:660-668
90. Babinchak T, Ellis-Grosse E, Dartois N, et al: The efficacy and safety of tigecycline for the treatment of complicated intraabdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005;41 Suppl 5:S354-367
91. Stass H, Rink AD, Delesen H, et al: Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother 2006;58:693-696
92. Dinubile MJ, Friedland I, Chan CY, et al: Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy. Eur J Clin Microbiol Infect Dis 2005;24:443-449
93. Lennard ES, Dellinger EP, Wertz MJ, Minshew BH: Implications of leukocytosis and fever at conclusion of antibiotic therapy for intra-abdominal sepsis. Ann Surg 1982;195:19-24
94. Stone HH, Bourneuf AA, Stinson LD: Reliability of criteria for predicting persistent or recurrent sepsis. Arch Surg 1985;120:17-20
95. Wittmann DH, Schein M, Condon RE: Management of secondary peritonitis. Ann Surg 1996;224:10-18
96. Solomkin JS, Reinhart HH, Dellinger EP, et al: Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann Surg 1996;223:303-315
97. Nathens AB, Cook CH, Machiedo G, et al: Defining the research agenda for surgical infection: a consensus of experts using the Delphi approach. Surg Infect 2006;7:101-110
98. Lennard ES, Minshew BH, Dellinger EP, Wertz M: Leukocytosis at termination of antibiotic therapy: its importance for intra-abdominal sepsis. Arch Surg 1980;115:918-921
99. Gorbach SL: Intraabdominal infections: Clin Infect Dis 1993;17:961-965
100. Harbarth S, Uckay I: Are there patients with peritonitis who require empiric therapy for enterococcus? Eur J Clin Microbiol Infect Dis 2004;23:73-77
101. Sirinek KR, Levine BA: A randomized trial of ticarcillin and clavulanate versus gentamicin and clindamycin in patients with complicated appendicitis. Surg Gynecol Obstet 1991;172 Suppl:30-35
102. Polk HC, Jr., Fink MP, Laverdiere M, et al: Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. The Piperacillin/Tazobactam Intra-Abdominal Infection Study Group. Am Surg 1993;59:598-605
103. Walker AP, Nichols RL, Wilson RF, et al: Efficacy of a beta-lactamase inhibitor combination for serious intraabdominal infections. Ann Surg 1993;217:115-121
104. Cohn SM, Lipsett PA, Buchman TG, et al: Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg 2000;232:254-262
105. Ohlin B, Cederberg A, Forssell H, et al: Piperacillin/tazobactam compared with cefuroxime/ metronidazole in the treatment of intra-abdominal infections. Eur J Surg 1999;165:875-884
106. Teppler H, McCarroll K, Gesser RM, Woods GL: Surgical infections with enterococcus: outcome in patients treated with ertapenem versus piperacillin-tazobactam. Surgical infections 2002;3:337-349
107. Zanetti G, Harbarth SJ, Trampuz A, et al: Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections. Int J Antimicrob Agents 1999;11:107-113
108. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709
109. Payen D, Sablotzki A, Barie PS, et al: International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort. Surgery 2006;140:726-739
110. Barie PS, Hydo LJ, Eachempati SR: Longitudinal outcomes of intra-abdominal infection complicated by critical illness. Surg Infect 2004;5:365-373
111. Dellinger EP, Wertz MJ, Meakins JL, et al: Surgical infection stratification system for intra-abdominal infection. Multicenter trial. Arch Surg 1985;120:21-29
112. Karamarkovic A, Radenkovic D, Milic N, et al: Protein C as an early marker of severe septic complications in diffuse secondary peritonitis. World J Surg 2005;29:759-765
113. Blot S, De Waele JJ: Critical issues in the clinical management of complicated intra-abdominal infections. Drugs 2005;65:1611-1620